West Pharmaceutical Services/$WST
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About West Pharmaceutical Services
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.
- Ticker
- $WST
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 10,800
- Headquarters
- Exton, United States
- Website
- www.westpharma.com
WST Metrics
BasicAdvanced
$26B
46.52
$7.81
1.14
$0.88
0.24%
Price and volume
Market cap
$26B
Beta
1.14
52-week high
$386.00
52-week low
$223.83
Average daily volume
576K
Dividend rate
$0.88
Financial strength
Current ratio
2.822
Quick ratio
1.819
Long term debt to equity
0.097
Total debt to equity
0.106
Dividend payout ratio (TTM)
11.05%
Interest coverage (TTM)
162.40%
Profitability
EBITDA (TTM)
912.2
Gross margin (TTM)
36.79%
Net profit margin (TTM)
16.98%
Operating margin (TTM)
21.97%
Effective tax rate (TTM)
20.34%
Revenue per employee (TTM)
$310,000
Management effectiveness
Return on assets (TTM)
11.38%
Return on equity (TTM)
19.09%
Valuation
Price to earnings (TTM)
46.517
Price to revenue (TTM)
7.846
Price to book
8.55
Price to tangible book (TTM)
8.9
Price to free cash flow (TTM)
59.741
Free cash flow yield (TTM)
1.67%
Free cash flow per share (TTM)
6.081
Dividend yield (TTM)
0.24%
Forward dividend yield
0.24%
Growth
Revenue change (TTM)
12.38%
Earnings per share change (TTM)
16.82%
3-year revenue growth (CAGR)
5.10%
10-year revenue growth (CAGR)
8.63%
3-year earnings per share growth (CAGR)
4.38%
10-year earnings per share growth (CAGR)
18.99%
3-year dividend per share growth (CAGR)
5.07%
10-year dividend per share growth (CAGR)
6.35%
What the Analysts think about WST
Analyst ratings (Buy, Hold, Sell) for West Pharmaceutical Services stock.
Analyst projections of the future price of West Pharmaceutical Services stock.
Bulls say / Bears say
West raised 2026 organic sales guidance to 10%-11% and adjusted EPS guidance to $8.85-$9.05 after a strong second quarter. Q2 revenue grew 12.7% organically and adjusted EPS rose 28.8%, showing that the recovery is translating into earnings. (Reuters, PR Newswire)
High-value component demand is broadening beyond GLP-1 drugs. West reported high-teens growth in both GLP-1 and non-GLP-1 components, supported by biologics and Annex 1 upgrades, while Reuters reported growing demand for generic GLP-1s in China, India and South Korea. (Reuters, PR Newswire)
West is adding commercial-scale drug-handling capacity in Dublin for high-volume injectable therapies, including next-generation GLP-1s. The 165,000-square-foot expansion could deepen customer relationships by combining component production, device assembly, packaging and drug handling in one offering. (PR Newswire, West Pharmaceutical Services)
West Vantage faces a near-term revenue gap as a major continuous glucose monitoring contract rolls off. Management expects the segment to decline in the third quarter, while replacement drug-handling work is still ramping and is not expected to reach more than $60 million annually until around 2028. (StockAnalysis, GoodMoat)
The May cyber incident exposed execution risk and contributed to weaker West Vantage profitability. Its second-quarter operating margin fell to 8.6% from 12.1% a year earlier, even as the proprietary-products business performed strongly. (StockTitan, PR Newswire)
The shares already discount a strong continuation of the growth story. A recent valuation review put West on roughly 45 times earnings versus about 38 times for the wider life-sciences industry, so any slowdown in GLP-1 demand, margins or execution could trigger a sharp re-rating. (Simply Wall St)
Data summarised monthly by Lightyear AI. Last updated on 22 Sept 2026.
WST Financial Performance
Revenues and expenses
WST Earnings Performance
Company profitability
Upcoming events
No upcoming events
WST News
AllArticlesVideos
Funds containing WST
AllEURGBPUSD
Fund name | Fund size | $WST weighting |
|---|---|---|
iShares S&P 500 Health Care Sector€IUHE | €125M | 0.42% |
iShares S&P 500 Equal Weight€O4J0 | €4.3B | 0.21% |
iShares S&P 500 Equal Weight£EWSP | £3.7B | 0.21% |
iShares MSCI USA SRI$SUAS | $3.4B | 0.18% |
iShares MSCI USA SRI€QDVR | €2.9B | 0.18% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.